YAP Activation Is Associated with a Worse Prognosis of Poorly Cohesive Gastric Cancer.
YAP expression
gastric cancer
poorly cohesive
tumor progression
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
24 Aug 2023
24 Aug 2023
Historique:
received:
02
05
2023
revised:
15
08
2023
accepted:
22
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Poorly cohesive (PC) gastric cancer (GC) is extremely aggressive in progression, and there is an urgent need to identify the molecular pathways involved. We hypothesized the essential role of the RhoA-YAP axis in these mechanisms. The present observational multicenter retrospective study included 133 patients with PC GC treated at two dedicated European surgical centers between 2004 and 2014. YAP nuclear localization was measured by immunohistochemical (IHC) analysis of tissue biopsies. The complete absence of nuclear reactivity was coded as negative expression; we considered "any positive" as low nuclear expression (>0% but <10% of cells) and high nuclear expression (≥10% of cells). Women represented about half of the present series (52%), and the median age was 64 years (p25-p75 range: 53-75). Neoadjuvant and adjuvant treatments were administered to 10% and 54% of the cases, respectively. Extended systemic lymphadenectomy (D2) was the most common (54%). In nearly all cases, the number of retrieved nodes was ≥15, i.e., adequate for tumor staging (94%). An R0 resection was achieved in 80% of the cases. Most patients were pathological T stage 3 and 4 (pT3/pT4 = 79.0%) and pathological N stage 2, 3a, and 3b (pN2/pN3a/pN3b = 47.0%) at the pathological examination. Twenty patients (15%) presented distant metastases. Five-year overall survival (OS) was significantly higher (
Identifiants
pubmed: 37763062
pii: jpm13091294
doi: 10.3390/jpm13091294
pmc: PMC10532557
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Gianesini
ID : xxx
Organisme : GIRCG
ID : xxx
Références
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3155-60
pubmed: 23382194
Cell Death Dis. 2023 Jan 12;14(1):21
pubmed: 36635265
Biochem Biophys Res Commun. 2017 Sep 16;491(2):493-499
pubmed: 28684311
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
Drug Des Devel Ther. 2021 Jun 09;15:2445-2456
pubmed: 34140763
Nat Rev Cancer. 2015 Feb;15(2):73-79
pubmed: 25592648
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Ann Surg. 2011 Nov;254(5):684-93; discussion 693
pubmed: 22005144
Nat Cancer. 2021 Sep;2(9):962-977
pubmed: 35121863
Mol Biol Cell. 2014 May;25(10):1676-85
pubmed: 24648494
Gut. 2023 Feb;72(2):226-241
pubmed: 35817555
Nat Genet. 2014 Jun;46(6):573-82
pubmed: 24816253
Eur J Med Chem. 2013;70:613-22
pubmed: 24211637
Cancer Immunol Res. 2018 Mar;6(3):255-266
pubmed: 29382670
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Int J Cancer. 2015 Dec 15;137(12):2767-73
pubmed: 25348697
Cancer Res. 2018 Mar 15;78(6):1457-1470
pubmed: 29339539
Ann Surg Oncol. 2014 May;21(5):1678-85
pubmed: 24394986
Physiol Rev. 2014 Oct;94(4):1287-312
pubmed: 25287865
Cancer Res. 1992 Dec 15;52(24):6735-40
pubmed: 1458460
J Cell Mol Med. 2018 Jun;22(6):3139-3148
pubmed: 29575535
Nat Commun. 2019 Jun 26;10(1):2797
pubmed: 31243273
Cancer Discov. 2020 Feb;10(2):288-305
pubmed: 31771969
Hum Pathol. 2008 Nov;39(11):1582-9
pubmed: 18703216
Histopathology. 2018 Mar;72(4):556-568
pubmed: 28873240
Nat Cell Biol. 1999 Sep;1(5):253-9
pubmed: 10559936
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Gastric Cancer. 2019 Jan;22(1):1-9
pubmed: 30167905